Report of Foreign Issuer (6-k)
December 18 2019 - 2:39PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
Report of Foreign Private Issuer Pursuant
to Rule 13a-16 or 15d-16
Under the Securities Exchange Act of 1934
For the Month of December 2019
011-36000
(Commission File Number)
XTL Biopharmaceuticals Ltd.
(Exact name of Registrant as specified in
its charter)
5 Badner St.
Ramat Gan, Israel, 5218102
(Address of principal executive offices)
Indicate by check
mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate by
check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T
Rule 101(b)(1): ____
Indicate by
check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T
Rule 101(b)(7): ____
On December 18, 2019, XTL Biopharmaceuticals
Ltd. (the “Company”) announced that it will hold an Annual General Meeting of Shareholders on January 22, 2020 at 10:00
a.m. (Israel time) at the offices of the Company's attorneys, Doron Tikotzky Kantor Gutman Nass & Amit Gross., 7 Metsada St.,
B.S.R Tower 4, 33 Floor, Bnei Brak, Israel. In connection with the meeting, the Company furnishes the following documents:
|
1.
|
A
copy of the Notice and Proxy Statement with respect to the Company’s Annual General Meeting of Shareholders describing the
proposals to be voted upon at the meeting, the procedure for voting in person or by proxy at the meeting and various other details
related to the meeting, attached hereto as Exhibit 99.1;
|
|
2.
|
A
form of Proxy Card whereby holders of ordinary shares of the Company may vote at the meeting without attending in person, attached
hereto as Exhibit 99.2; and
|
|
3.
|
A
form of Voting Instruction Card whereby holders of American Depositary Shares of the Company may vote at the meeting without attending
in person, attached hereto as Exhibit 99.3.
|
Exhibit Index
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.
|
XTL BIOPHARMACEUTICALS LTD.
|
|
|
|
Date: December 18, 2019
|
By:
|
/s/ Josh Levine
|
|
|
Josh Levine
|
|
|
Chief Executive Officer
|
3
XTL Biopharmaceuticals (NASDAQ:XTLB)
Historical Stock Chart
From Oct 2024 to Nov 2024
XTL Biopharmaceuticals (NASDAQ:XTLB)
Historical Stock Chart
From Nov 2023 to Nov 2024